BI 765063 / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   63 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 765063 / Boehringer Ingelheim
NCT03990233: A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Checkmark From trial in combination with BI 754091 for solid tumors
Jun 2021 - Jun 2021: From trial in combination with BI 754091 for solid tumors
Active, not recruiting
1
116
Europe
BI 765063, OSE-172, BI 754091
OSE Immunotherapeutics, Boehringer Ingelheim
Solid Tumor, Adult
04/23
12/25
NCT05446129: A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Terminated
1
2
US
Ezabenlimab, BI 765063, Pembrolizumab
Boehringer Ingelheim
Colorectal Cancer
08/23
11/23
NCT05068102: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Recruiting
1
13
Europe
BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063, BI 770371, [89Zr]Zr- BI 770371
Boehringer Ingelheim
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
01/25
03/25
NCT05249426: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active, not recruiting
1
48
Europe, Japan, US, RoW
BI 765063, Ezabenlimab, BI 754091, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma (HNSCC)
11/24
08/25

Download Options